172 related articles for article (PubMed ID: 36336580)
21. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications.
Xing M
Endocr Rev; 2007 Dec; 28(7):742-62. PubMed ID: 17940185
[TBL] [Abstract][Full Text] [Related]
22. To treat or not to treat: developments in the field of advanced differentiated thyroid cancer.
Schneider TC; Kapiteijn E; Corssmit EP; Oosting SF; van der Horst-Schrivers AN; Links TP
Neth J Med; 2014 Oct; 72(8):401-6. PubMed ID: 25387552
[TBL] [Abstract][Full Text] [Related]
23.
Pekova B; Sykorova V; Dvorakova S; Vaclavikova E; Moravcova J; Katra R; Astl J; Vlcek P; Kodetova D; Vcelak J; Bendlova B
Thyroid; 2020 Dec; 30(12):1771-1780. PubMed ID: 32495721
[No Abstract] [Full Text] [Related]
24. Systemic treatment and management approaches for medullary thyroid cancer.
Ernani V; Kumar M; Chen AY; Owonikoko TK
Cancer Treat Rev; 2016 Nov; 50():89-98. PubMed ID: 27664392
[TBL] [Abstract][Full Text] [Related]
25. Novel chemotherapy options for advanced thyroid tumors: small molecules offer great hope.
Deshpande HA; Gettinger SN; Sosa JA
Curr Opin Oncol; 2008 Jan; 20(1):19-24. PubMed ID: 18043252
[TBL] [Abstract][Full Text] [Related]
26. Safety Profiles and Pharmacovigilance Considerations for Recently Patented Anticancer Drugs: Advanced Thyroid Cancer.
Vaccher E; Schioppa O; Martellotta F; Fornasier G; Giacomin E; Re FL; Baldo P; Corona G; Gobitti C
Recent Pat Anticancer Drug Discov; 2019; 14(3):226-241. PubMed ID: 31362663
[TBL] [Abstract][Full Text] [Related]
27. Targeted therapies in advanced differentiated thyroid cancer.
Carneiro RM; Carneiro BA; Agulnik M; Kopp PA; Giles FJ
Cancer Treat Rev; 2015 Sep; 41(8):690-8. PubMed ID: 26105190
[TBL] [Abstract][Full Text] [Related]
28. New therapies for anaplastic thyroid cancer.
Agrawal VR; Hreno J; Patil T; Bowles DW
Drugs Today (Barc); 2018 Nov; 54(11):695-704. PubMed ID: 30539168
[TBL] [Abstract][Full Text] [Related]
29. Potent inhibition of thyroid cancer cells by the MEK inhibitor PD0325901 and its potentiation by suppression of the PI3K and NF-kappaB pathways.
Liu D; Xing M
Thyroid; 2008 Aug; 18(8):853-64. PubMed ID: 18651802
[TBL] [Abstract][Full Text] [Related]
30. How I treat medullary thyroid cancer.
Kiesewetter B; Riss P; Scheuba C; Raderer M
ESMO Open; 2021 Jun; 6(3):100183. PubMed ID: 34091261
[TBL] [Abstract][Full Text] [Related]
31. Targeted therapy in lung cancer: Are we closing the gap in years of life lost?
Benjamin DJ; Haslam A; Gill J; Prasad V
Cancer Med; 2022 Sep; 11(18):3417-3424. PubMed ID: 35315222
[TBL] [Abstract][Full Text] [Related]
32. Resistance to RET targeted therapy in Thyroid Cancer: Molecular basis and overcoming strategies.
Román-Gil MS; Pozas J; Rosero-Rodríguez D; Chamorro-Pérez J; Ruiz-Granados Á; Caracuel IR; Grande E; Molina-Cerrillo J; Alonso-Gordoa T
Cancer Treat Rev; 2022 Apr; 105():102372. PubMed ID: 35248904
[TBL] [Abstract][Full Text] [Related]
33. Outcome of Patients with Locally Advanced Metastatic Medullary Thyroid Cancer and Induction Therapy with Tyrosine Kinase Inhibitors in Slovenia.
Grasic Kuhar C; Lozar T; Besic N; Music Marolt M
Adv Ther; 2021 Dec; 38(12):5684-5699. PubMed ID: 34674146
[TBL] [Abstract][Full Text] [Related]
34. NTRK and RET fusion-directed therapy in pediatric thyroid cancer yields a tumor response and radioiodine uptake.
Lee YA; Lee H; Im SW; Song YS; Oh DY; Kang HJ; Won JK; Jung KC; Kwon D; Chung EJ; Hah JH; Paeng JC; Kim JH; Choi J; Kim OH; Oh JM; Ahn BC; Wirth LJ; Shin CH; Kim JI; Park YJ
J Clin Invest; 2021 Sep; 131(18):. PubMed ID: 34237031
[TBL] [Abstract][Full Text] [Related]
35. From nodule to differentiated thyroid carcinoma: contributions of molecular analysis in 2012.
Albarel F; Conte-Devolx B; Oliver C
Ann Endocrinol (Paris); 2012 Jun; 73(3):155-64. PubMed ID: 22503804
[TBL] [Abstract][Full Text] [Related]
36. This is Your Thyroid on Drugs: Targetable Mutations and Fusions in Thyroid Carcinoma.
Chu YH
Surg Pathol Clin; 2023 Mar; 16(1):57-73. PubMed ID: 36739167
[TBL] [Abstract][Full Text] [Related]
37. Perspectives on the Treatment of Advanced Thyroid Cancer: Approved Therapies, Resistance Mechanisms, and Future Directions.
Porter A; Wong DJ
Front Oncol; 2020; 10():592202. PubMed ID: 33569345
[TBL] [Abstract][Full Text] [Related]
38. NTRK fusion oncogenes in pediatric papillary thyroid carcinoma in northeast United States.
Prasad ML; Vyas M; Horne MJ; Virk RK; Morotti R; Liu Z; Tallini G; Nikiforova MN; Christison-Lagay ER; Udelsman R; Dinauer CA; Nikiforov YE
Cancer; 2016 Apr; 122(7):1097-107. PubMed ID: 26784937
[TBL] [Abstract][Full Text] [Related]
39. Interstitial lung disease associated with combination therapy of dabrafenib and trametinib in metastatic BRAF
Zeng Q; Deng Y; Zhang L; Wang W
Int J Clin Pharmacol Ther; 2022 May; 60(5):225-231. PubMed ID: 35072623
[TBL] [Abstract][Full Text] [Related]
40. Update on Targeted Therapy in Medullary Thyroid Cancer.
Okafor C; Hogan J; Raygada M; Thomas BJ; Akshintala S; Glod JW; Del Rivero J
Front Endocrinol (Lausanne); 2021; 12():708949. PubMed ID: 34489865
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
